The stock of Cardiol Therapeutics Inc (CRDL) has gone down by -3.64% for the week, with a -4.93% drop in the past month and a 45.21% rise in the past quarter. The volatility ratio for the week is 13.23%, and the volatility levels for the past 30 days are 10.96% for CRDL. The simple moving average for the last 20 days is -12.78% for CRDL stock, with a simple moving average of 52.98% for the last 200 days.
Is It Worth Investing in Cardiol Therapeutics Inc (NASDAQ: CRDL) Right Now?
The stock has a 36-month beta value of 0.99. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRDL is 65.92M, and at present, short sellers hold a 0.40% of that float. On June 26, 2024, the average trading volume of CRDL was 502.39K shares.
CRDL) stock’s latest price update
Cardiol Therapeutics Inc (NASDAQ: CRDL) has seen a rise in its stock price by 6.00 in relation to its previous close of 2.00. However, the company has experienced a -3.64% decline in its stock price over the last five trading sessions. newsfilecorp.com reported 2024-06-25 that Toronto, Ontario–(Newsfile Corp. – June 25, 2024) – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General and Special Meeting of Shareholders (the “AGM”) will be webcast on June 26, 2024, at 4:30 p.m. EDT. Cardiol Therapeutics 2024 AGM When: June 26, 2024, at 4:30 p.m.
Analysts’ Opinion of CRDL
Many brokerage firms have already submitted their reports for CRDL stocks, with H.C. Wainwright repeating the rating for CRDL by listing it as a “Buy.” The predicted price for CRDL in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on April 22, 2024 of the current year 2024.
CRDL Trading at -2.16% from the 50-Day Moving Average
After a stumble in the market that brought CRDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.05% of loss for the given period.
Volatility was left at 10.96%, however, over the last 30 days, the volatility rate increased by 13.23%, as shares sank -9.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.98% upper at present.
During the last 5 trading sessions, CRDL fell by -3.64%, which changed the moving average for the period of 200-days by +118.56% in comparison to the 20-day moving average, which settled at $2.42. In addition, Cardiol Therapeutics Inc saw 151.42% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CRDL
The total capital return value is set at -1.42. Equity return is now at value -92.40, with -72.33 for asset returns.
Based on Cardiol Therapeutics Inc (CRDL), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -132.57.
Currently, EBITDA for the company is -29.54 million with net debt to EBITDA at 0.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.81.
Conclusion
To sum up, Cardiol Therapeutics Inc (CRDL) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
